Related Experiment Video
Updated: May 9, 2026
10:40
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
Published on: April 25, 2022
XPC gene polymorphisms contribute to bladder cancer susceptibility: a meta-analysis
Qiang-Sheng Dai1, Rui-Xi Hua, Rui-Fang Zeng
1Department of Oncology, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, People's Republic of China, mddaiqs@163.com.
Summary
This meta-analysis found that Xeroderma pigmentosum group C (XPC) gene polymorphisms are linked to increased bladder cancer risk. Specific variants like Lys939Gln, Ala499Val, and PAT-/+ show associations, particularly in certain ethnic groups.
Area of Science:
- Genetics and Cancer Epidemiology
- Molecular Biology and Disease Mechanisms
Background:
- The Xeroderma pigmentosum group C (XPC) gene plays a crucial role in DNA repair pathways.
- Genetic variations within the XPC gene, specifically polymorphisms like Lys939Gln, Ala499Val, and PAT-/+, have been investigated for their potential link to bladder cancer susceptibility.
- Previous studies on these associations have yielded inconclusive results, necessitating a comprehensive analysis.
Purpose of the Study:
- To conduct a meta-analysis to precisely estimate the association between three XPC gene polymorphisms (Lys939Gln, Ala499Val, and PAT-/+) and bladder cancer risk.
- To explore potential ethnic differences in the observed associations.
Main Methods:
- A meta-analysis was performed using data from 10 studies for Lys939Gln, 5 for Ala499Val, and 7 for PAT-/+.
- Publications were systematically searched from EMBASE, MEDLINE, and Chinese Biomedical databases.
- Pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated using fixed-effects or random-effects models based on heterogeneity.
Main Results:
- All three studied XPC polymorphisms (Lys939Gln, Ala499Val, and PAT-/+) were individually associated with an increased overall risk of bladder cancer.
- Specific ORs and CIs were reported for different genotypic and allelic comparisons.
- Stratification analyses revealed increased risk for Asian populations with Lys939Gln and PAT-/+, and for Caucasian populations with Ala499Val in homozygous and recessive models.
Conclusions:
- The meta-analysis suggests that XPC polymorphisms are associated with bladder cancer risk.
- The Lys939Gln and PAT-/+ polymorphisms show increased risk in Asian populations, while Ala499Val is associated with increased risk in Caucasian populations.
- Further validation in large-scale, well-designed studies is warranted to confirm these findings.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...